In Taiwan, 20-40% of liver cirrhosis patients will affect hepatoma and 60-90% of hepatoma patients combine with liver cirrhosis. Moreover, 80-90% of hepatoma patients are Hepatitis B carriers and 10% of hepatoma patients are Hepatitis C carriers. In this reported case, there was a 60 years old male. He was a Hepatitis B carrier and affected liver cirrhosis and hepatocellular carcinoma. After treated with traditional Chinese medicine (TCM), the GTP level was reduced and the APF level descended to the normal value. These therapeutic effects confirm that the treatments of TCM are benefits for patient with liver cirrhosis and hepatocellular carcinoma.